Ann Arbor staging system (historical)
- Integral Diagnostics, Shareholder (ongoing)
- Micro-X Ltd, Shareholder (ongoing)
Updates to Article Attributes
The Ann Arbor staging system was the landmark lymphoma staging classification system for both Hodgkin lymphoma and and non-Hodgkin lymphoma. It It is named after the town of Ann Arbor in the US state of Michigan where the Committee on Hodgkin's Disease Staging Classification met in 1971 to agree on it. It updated and replaced the earlier Rye staging system2.
Usage
This classification has since been updated and modified, with the currently used criteria being the Lugano classification and and the LYRIC classificationref.
Staging system
stage I:
involvementinvolvement of a single lymph node region or of a single extralymphatic organ or sitestage II:
involvementinvolvement of two or more lymph node regions on the same side of the diaphragm or localised involvement of an extralymphatic organ or sitestage III:
involvementinvolvement of lymph node regions or structures on both sides of the diaphragm-
stage IV:
diffusediffuse or disseminated involvement of one or more extralymphatic organs, or either:isolated extralymphatic organ involvement without adjacent regional lymph node involvement, but with disease in distant sites
involvement of the liver, bone marrow, pleura or cerebrospinal fluid
Additional substaging variables include:
A:asymptomatic
B:
presencepresence of B symptoms (including fever, night sweats and weight loss of ≥10% of body weight over 6 months)E: involvement of a single, extranodal site, contiguous or proximal to a known nodal site (stages I to III only; additional extranodal involvement is stage IV)
S: splenic involvement
X:
bulkybulky nodal disease: nodal mass >1/3 of intrathoracic diameter or 10 cm in dimension
-<p>The <strong>Ann Arbor staging system</strong> was the landmark <a href="/articles/lymphoma-staging-1">lymphoma staging</a> classification system for both <a href="/articles/hodgkin-lymphoma">Hodgkin lymphoma</a> and <a href="/articles/non-hodgkin-lymphoma">non-Hodgkin lymphoma</a>. It is named after the town of Ann Arbor in the US state of Michigan where the Committee on Hodgkin's Disease Staging Classification met in 1971 to agree on it. It updated and replaced the earlier <a href="/articles/rye-staging-system">Rye staging system</a> <sup>2</sup>. </p><p>This classification has since been updated and modified, with the currently used criteria being the <a href="/articles/lugano-staging-classification-1">Lugano classification</a> and the <a href="/articles/lymphoma-response-to-immunomodulatory-therapy-criteria-lyric">LYRIC classification</a>.</p><h4>Staging system</h4><ul>-<li>-<strong>stage I:</strong> involvement of a single lymph node region or of a single extralymphatic organ or site</li>-<li>-<strong>stage II:</strong> involvement of two or more lymph node regions on the same side of the diaphragm or localised involvement of an extralymphatic organ or site </li>-<li>-<strong>stage III:</strong> involvement of lymph node regions or structures on both sides of the diaphragm</li>-<li>-<strong>stage IV:</strong> diffuse or disseminated involvement of one or more extralymphatic organs, or either: <ul>-<li>isolated extralymphatic organ involvement without adjacent regional lymph node involvement, but with disease in distant sites</li>-<li>involvement of the liver, bone marrow, pleura or cerebrospinal fluid</li>- +<p>The <strong>Ann Arbor staging system</strong> was the landmark <a href="/articles/lymphoma-staging-1">lymphoma staging</a> classification system for both <a href="/articles/hodgkin-lymphoma">Hodgkin lymphoma</a> and <a href="/articles/non-hodgkin-lymphoma">non-Hodgkin lymphoma</a>. It is named after the town of Ann Arbor in the US state of Michigan where the Committee on Hodgkin's Disease Staging Classification met in 1971 to agree on it. It updated and replaced the earlier <a href="/articles/rye-staging-system">Rye staging system</a> <sup>2</sup>. </p><h4>Usage</h4><p>This classification has since been updated and modified, with the currently used criteria being the <a href="/articles/lugano-staging-classification-1">Lugano classification</a> and the <a href="/articles/lymphoma-response-to-immunomodulatory-therapy-criteria-lyric">LYRIC classification</a> <sup>ref</sup>.</p><h4>Staging system</h4><ul>
- +<li><p><strong>stage I:</strong> involvement of a single lymph node region or of a single extralymphatic organ or site</p></li>
- +<li><p><strong>stage II:</strong> involvement of two or more lymph node regions on the same side of the diaphragm or localised involvement of an extralymphatic organ or site </p></li>
- +<li><p><strong>stage III:</strong> involvement of lymph node regions or structures on both sides of the diaphragm</p></li>
- +<li>
- +<p><strong>stage IV:</strong> diffuse or disseminated involvement of one or more extralymphatic organs, or either: </p>
- +<ul>
- +<li><p>isolated extralymphatic organ involvement without adjacent regional lymph node involvement, but with disease in distant sites</p></li>
- +<li><p>involvement of the liver, bone marrow, pleura or cerebrospinal fluid</p></li>
-<li>-<strong>A: </strong>asymptomatic</li>-<li>-<strong>B:</strong> presence of <a href="/articles/b-symptoms">B symptoms</a> (including <a href="/articles/pyrexia">fever</a>, <a title="Night sweats" href="/articles/night-sweats">night sweats</a> and <a title="Weight loss" href="/articles/weight-loss">weight loss</a> of ≥10% of body weight over 6 months)</li>-<li>-<strong>E</strong>: involvement of a single, extranodal site, contiguous or proximal to a known nodal site (stages I to III only; additional extranodal involvement is stage IV)</li>-<li>-<strong>S</strong>: splenic involvement</li>-<li>-<strong>X:</strong> bulky nodal disease: nodal mass >1/3 of intrathoracic diameter or 10 cm in dimension</li>- +<li><p><strong>A: </strong>asymptomatic</p></li>
- +<li><p><strong>B:</strong> presence of <a href="/articles/b-symptoms">B symptoms</a> (including <a href="/articles/pyrexia">fever</a>, <a href="/articles/night-sweats" title="Night sweats">night sweats</a> and <a href="/articles/weight-loss" title="Weight loss">weight loss</a> of ≥10% of body weight over 6 months)</p></li>
- +<li><p><strong>E</strong>: involvement of a single, extranodal site, contiguous or proximal to a known nodal site (stages I to III only; additional extranodal involvement is stage IV)</p></li>
- +<li><p><strong>S</strong>: splenic involvement</p></li>
- +<li><p><strong>X:</strong> bulky nodal disease: nodal mass >1/3 of intrathoracic diameter or 10 cm in dimension</p></li>
Tags changed:
- cases
- case3
- refs
Unable to process the form. Check for errors and try again.